Track topics on Twitter Track topics that are important to you
eFFECTOR Therapeutics, Pfizer, and Merck KGaA established a partnership to carry out Phase II study evaluating the safety, tolerability, and efficacy of eFFECTOR’s small-molecule investigational MNK1/2 (MAP kinase-interacting kinase 1 and 2) inhibitor eFT508 combined with Merck KGaA’s and Pfizer’s programmed death-ligand 1 (PD-L1) antibody avelumab (Bavencio ® ) in patients with microsatellite-stable relapsed or refractory colorectal cancer (CRC). eFFECTOR will conduct the noncomparative study, which is projected to start during the third quarter of this year, and will also include an eFT508 montherapy arm. Pfizer and Merck KGaA will share associated trial costs. "We believe eFT508, our lead program, is a promising new immuno-oncology drug candidate that could significantly improve patient response in combination with checkpoint inhibitors," said Steve Worland, Ph.D., president and CEO at eFFECTOR. "We look forward to exploring the potential of this novel combination and the role we hope it may eventually ...NEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...